NCT03986424

Local Study of Akatinol Memantine in VaD in Russia

Multi-center Open Comparative Randomized Study of Efficacy and Safety of Akatinol Memantine 20 mg (Single-doses) vs. Akatinol Memantine 10 mg (Double-doses) in Patients With Moderate and Moderately Severe Vascular Dementia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: Merz Pharmaceuticals GmbH · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The study evaluates the clinical efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs. Akatinol Memantine 10 mg (double-doses) in patients suffering from moderate and moderately severe vascular dementia.

Conditions

• Vascular Dementia

Interventions

Type	Name	Description
DRUG	Akatinol Memantine 20 mg	Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
DRUG	Akatinol Memantine 10 mg	Akatinol Memantine 10 mg to be taken orally, twice daily

Timeline

• Start date: 2018-01-23
• Primary completion: 2022-06-01
• Completion: 2022-06-01
• First posted: 2019-06-14
• Last updated: 2022-07-22

Locations

4 sites across 1 country: Russia